Loefflers syndrome differential diagnosis: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 12: | Line 12: | ||
! colspan="2" rowspan="4" |Diseases | ! colspan="2" rowspan="4" |Diseases | ||
| colspan="6" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations''' | | colspan="6" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Clinical manifestations''' | ||
! colspan=" | ! colspan="6" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Para-clinical findings | ||
| colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard''' | | colspan="1" rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |'''Gold standard''' | ||
! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ! rowspan="4" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Additional findings | ||
Line 19: | Line 19: | ||
! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination | ! colspan="3" rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical examination | ||
|- | |- | ||
! colspan=" | ! colspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Lab Findings | ||
! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ! colspan="3" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Imaging | ||
! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ! rowspan="2" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Histopathology | ||
Line 29: | Line 29: | ||
! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 2 | ! colspan="1" rowspan="1" style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 2 | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 3 | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Physical exam 3 | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Increased Eosinophil | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Increased Eosinophil | ||
count | |||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other lab findings | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |Other lab findings | ||
! style="background: #4479BA; color: #FFFFFF; text-align: center;" |CXR | ! style="background: #4479BA; color: #FFFFFF; text-align: center;" |CXR | ||
Line 51: | Line 50: | ||
Fever | Fever | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 89: | Line 87: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* 40 to 70 percent (>3000/microL) plus elevated IgE levels ( >1000 units/mL) | * 40 to 70 percent (>3000/microL) plus elevated IgE levels ( >1000 units/mL) | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 114: | Line 111: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |Mild to moderate | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 140: | Line 136: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |Mild to | ||
moderate to | |||
high | |||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* '''Trichinellosis:''' Ab will be positive 2-8 weeks after infection | * '''Trichinellosis:''' Ab will be positive 2-8 weeks after infection | ||
Line 167: | Line 165: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| | | style="background: #F5F5F5; padding: 5px;" | | ||
* Eosinophilia is prominent in the early stages of disease but minimal with established disease | * Eosinophilia is prominent in the early stages of disease but minimal with established disease | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 186: | Line 184: | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Coccidioidomycosis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Coccidioidomycosis | ||
| rowspan="2" style="background: #F5F5F5; padding: 5px;" |Manifests as a community-acquired pneumonia (CAP) approximately 7 to 21 days after exposure | | rowspan="2" style="background: #F5F5F5; padding: 5px;" |Manifests as a community-acquired pneumonia (CAP) approximately 7 to 21 days after exposure | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 203: | Line 200: | ||
|- | |- | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Mycobacterium tuberculosis | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Mycobacterium tuberculosis | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 231: | Line 227: | ||
* <small>1500 cells/microL</small> | * <small>1500 cells/microL</small> | ||
* <small>> 10 percent of the total leukocyte count</small> | * <small>> 10 percent of the total leukocyte count</small> | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* Antineutrophil cytoplasmic antibodies (ANCA) | * Antineutrophil cytoplasmic antibodies (ANCA) | ||
Line 259: | Line 254: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |Mild to moderate | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 278: | Line 272: | ||
| | | | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Acute eosinophilic pneumonia | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Acute eosinophilic pneumonia | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 317: | Line 310: | ||
* ≥40 percent | * ≥40 percent | ||
* Eosinophilia may be absent in 10-20% of patients | * Eosinophilia may be absent in 10-20% of patients | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 346: | Line 338: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
* ≥25 percent | * ≥25 percent | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 364: | Line 355: | ||
!Increased Eosinophil count | !Increased Eosinophil count | ||
(High) | (High) | ||
!Other lab findings | !Other lab findings | ||
!CXR | !CXR | ||
Line 382: | Line 371: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |Mild to moderate | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 400: | Line 388: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" |Mild to moderate | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 419: | Line 406: | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" |<10 percent | | style="background: #F5F5F5; padding: 5px;" |<10 percent | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
Line 430: | Line 416: | ||
| | | | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |Differential Diagnosis 7 | | style="background: #DCDCDC; padding: 5px; text-align: center;" |Differential Diagnosis 7 | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | | ||
| style="background: #F5F5F5; padding: 5px;" | | | style="background: #F5F5F5; padding: 5px;" | |
Revision as of 16:41, 21 May 2019
![](/images/1/16/Home_logo1.png)
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Soroush Seifirad, M.D.[2]
Overview
Loeffler syndrome must be differentiated from other diseases that cause pulmonary eosinophilia, such as Churg-Strauss, drug and toxin-induced eosinophilic lung diseases, other helminthic and fungal infection related eosinophilic lung diseases, and nonhelminthic infections such as Coccidioidomycosis, and Mycobacterium tuberculosis.
Differentiating Loeffler syndrome from other pulmonary eosinophilia syndromes on the basis of etiology.
Diseases | Clinical manifestations | Para-clinical findings | Gold standard | Additional findings | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Symptoms | Physical examination | ||||||||||||||
Lab Findings | Imaging | Histopathology | |||||||||||||
Physical exam 2 | Physical exam 3 | Increased Eosinophil
count |
Other lab findings | CXR | CT Scan | Imaging 3 | |||||||||
Helminthic
and fungal infection-related eosinophilic lung diseases |
Transpulmonary
passage of larvae (Loffler's syndrome) |
Cough
Sputum production Wheezing Fever |
|
| |||||||||||
Tropical
pulmonary eosinophilia |
cough, breathlessness, wheezing, fatigue, and fever. |
|
|
|
| ||||||||||
Allergic bronchopulmonary aspergillosis | Mild to moderate | ||||||||||||||
Heavy
hematogenous seeding with helminths |
depends on the organism for example:
periorbital edema, myositis, and eosinophilia (Trichinellosis) |
Mild to
moderate to high |
|
|
| ||||||||||
Pulmonary parenchymal invasion |
|
|
|
|
| ||||||||||
Nonhelminthic infections | Coccidioidomycosis | Manifests as a community-acquired pneumonia (CAP) approximately 7 to 21 days after exposure |
|
||||||||||||
Mycobacterium tuberculosis | |||||||||||||||
Eosinophilic granulomatosis with polyangiitis (Churg-Strauss) |
|
|
|
|
|
||||||||||
Drug- and toxin-induced eosinophilic lung diseases |
|
Mild to moderate |
| ||||||||||||
Acute eosinophilic pneumonia |
|
|
| ||||||||||||
Chronic eosinophilic pneumonia |
|
|
|
|
|||||||||||
Idiopathic acute eosinophilic pneumonia |
|
||||||||||||||
Diseases | Symptom 1 | Symptom 2 | Symptom 3 | Physical exam 1 | Physical exam 2 | Physical exam 3 | Increased Eosinophil count
(High) |
Other lab findings | CXR | CT Scan | Imaging 3 | Histopathology | Gold standard | Additional findings | |
Sarcoidosis | Mild to moderate | ||||||||||||||
Pulmonary Langerhans cell histiocytosis (Histiocytosis X) | Mild to moderate | ||||||||||||||
Idiopathic pulmonary fibrosis | <10 percent | ||||||||||||||
Differential Diagnosis 7 |